2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-162229
    GRL-190-21
    		Inhibitor
    GRL-190-21 (compound 5e) is an inhibitor for SARS-Cov-2-Mpro with a Ki of 0.04 nM and exhibits antiviral activity in VeroE6 cells with EC50 of 0.26 μM. GRL-190-21 reduces the infectivity, replication, and cytopathic effect of SARS-CoV-2 without significant toxicity.
    GRL-190-21
  • HY-176211
    SARS-CoV-2 Mpro-IN-45
    		Inhibitor
    SARS-CoV-2 Mpro-IN-45 (compound 28f) is an orally active Mpro inhibitor with IC50 values of 0.12 and 0.16 μM for HCoV-OC43 Mpro and SARS-CoV-2 Mpro, respectively. SARS-CoV-2 Mpro-IN-45 exhibits antiviral activity.
    SARS-CoV-2 Mpro-IN-45
  • HY-144747
    Hydroxyethylamine
    		Inhibitor
    Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC50 of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities.
    Hydroxyethylamine
  • HY-B0402R
    Amantadine (Standard)
    		Inhibitor
    Amantadine (Standard) is the analytical standard of Amantadine. This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[4].
    Amantadine (Standard)
  • HY-178160
    SARS-CoV-2 PLpro-IN-2
    		Inhibitor
    SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC50=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC50=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19.
    SARS-CoV-2 PLpro-IN-2
  • HY-150624
    SARS-CoV-2 nsp13-IN-3
    		Inhibitor
    SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA+ ATPase.
    SARS-CoV-2 nsp13-IN-3
  • HY-151991
    SARS-CoV-2/MERS Mpro-IN-2
    		Inhibitor
    SARS-CoV-2/MERS Mpro-IN-2 (compound 9d) is a potent SARS-CoV-2 and MERS main protease inhibitor with IC50 values of 0.21, 0.07 µM, respectively.
    SARS-CoV-2/MERS Mpro-IN-2
  • HY-168564
    SARS-CoV-2 3CLpro-IN-27
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC50 value of 5 nM.
    SARS-CoV-2 3CLpro-IN-27
  • HY-159655
    PLpro-IN-6
    		Inhibitor
    PLpro-IN-6 (compound 6) is a papain-like protease (PLpro) inhibitor, with an IC50 of 0.019 μM for SARS CoV2 PLpro enzyme.
    PLpro-IN-6
  • HY-155843
    CDK9-IN-25
    		Inhibitor
    CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM).
    CDK9-IN-25
  • HY-178135
    SCR005
    		Inhibitor
    SCR005 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR005 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR005 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR005 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR005 can be used for the study and prevention of enveloped virus pandemics.
    SCR005
  • HY-158347
    SARS-CoV-2 Mpro-IN-15
    		Inhibitor
    SARS-CoV-2 Mpro-IN-15 (8E) is a SARS-CoV-2 Mpro inhibitor, with an IC50 of  0.606 µM.
    SARS-CoV-2 Mpro-IN-15
  • HY-P11012
    EK1
    		Inhibitor
    EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats.
    EK1
  • HY-149940
    SIMR3030
    		Inhibitor
    SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice.
    SIMR3030
  • HY-183185
    BZ-30
    		Inhibitor
    BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.
    BZ-30
  • HY-149655
    D1N8
    		Inhibitor
    D1N8 is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 and CC50 values of 0.44 μM and >20 μM, respectively. D1N8 has the potential for the research of anti-SARS-CoV-2 agents targeting 3CLpro.
    D1N8
  • HY-W753281R
    Dexamethasone metasulfobenzoate sodium (Standard)
    		Inhibitor
    Dexamethasone metasulfobenzoate (sodium) (Standard) is the analytical standard of Dexamethasone metasulfobenzoate (sodium). This product is intended for research and analytical applications. Dexamethasone metasulfobenzoate sodium is a SARS-CoV-2 exonuclease (ExoN) inhibitor that binds to the catalytic site of ExoN.
    Dexamethasone metasulfobenzoate sodium (Standard)
  • HY-161365
    PLpro-IN-2
    		Inhibitor
    PLpro-IN-2 (Compound 16) is an inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 0.25 μM.
    PLpro-IN-2
  • HY-145643
    Nepuvibart
    		Inhibitor
    Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease.
    Nepuvibart
  • HY-P990725
    Nisfevitug
    Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Nisfevitug
Cat. No. Product Name / Synonyms Species Source